Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fedratinib with ropeginterferon alfa-2b in myelofibrosis
ISRCTN88102629Phase 2Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of fedratinib and ropeginterferon alfa-2b in myelofibrosis (MF), sponsored by University of Birmingham. Primary endpoint: Tolerability of combination therapy within 4 months. Started Sep 2022; status: active, not recruiting.
02
Drugs
fedratinibropeginterferon alfa-2b
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on ISRCTN88102629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN88102629.